大黄素对脂肪变性LO2肝细胞UCP2 mRNA表达的影响
|
摘要
目的:
观察大黄素对脂肪变性L02肝细胞UCP2 mRNA表达的影响,探讨其对脂变肝细胞的降脂作用和机制。
方法:
1.复制模型:以L02肝细胞为研究对象,用含50%小牛血清的1640培养基孵育L02肝细胞48h,建立肝细胞脂肪变性模型,用油红O染色,倒置显微镜观察肝细胞的脂滴积聚情况,检测细胞培养上清肝酶(ALT、AST、ALP、LDH)和细胞内甘油三酯(TG)的变化。
2.筛选药物浓度:采用MTT法测定大黄素作用于脂肪变性肝细胞的适宜浓度。
3.指标检测:模型复制成功后,分为4组:模型组、自然恢复组、大黄素高剂量组、大黄素低剂量组,同时设立正常对照组。药物作用24h、48h后,分别采用全自动生化分析仪检测肝细胞内TG含量的变化。采用RT-PCR法检测各组孵育24h后肝细胞內UCP2 mRNA的表达。
结果:
1.肝细胞脂肪变性模型:成功建立了高浓度小牛血清诱导的L02肝细胞脂肪变性模型,油红O染色显示,模型组在培养24h、48h、72h后,细胞内有逐渐增多的橘红色和红色的脂滴出现,而正常组细胞内则少见。与正常组比较,造模24h后细胞上清AST、LDH含量显著升高(P＜0.01),ALT、ALP未见有显著变化(P＞0.05),肝细胞中TG含量明显升高(P＜0.01);在48h、72h时段,则ALT、AST、ALP、LDH和TG水平都显著升高(P＜0.5,或P＜0.01)。
2.肝脂:大黄素治疗24h后,自然恢复组肝细胞內TG含量与模型组比较明显降低(P＜0.01);与自然恢复组比较,大黄素10μM组肝细胞内TG含量明显降低,差异有统计学意义(P＜0.05),而5μM组无明显降低(P＞0.05)。油红O染色结果显示,模型组细胞浆内见大量橘红色和红色的脂滴,正常组、自然恢复组和大黄素治疗组细胞浆内脂滴数和脂滴的颜色较模型组明显减少,其中大黄素10μM组减少最明显。大黄素治疗48h后,自然恢复组和各治疗组之间无显著性差异(P＞0.05)。油红O染色结果显示,模型组细胞浆内见大量橘红色和红色的脂滴,正常组、自然恢复组和大黄素治疗组细胞浆内脂滴数和脂滴的颜色较模型组明显减少。但大黄素各治疗组与自然恢复组之间比较镜下观察无明显差异。
3.肝细胞UCP2 mRNA的表达:大黄素治疗24t3后,与正常组比较,模型组肝细胞UCP2mRNA表达明显上升,差异有显著性(P＜0.01);各治疗组与自然恢复组比较,UCP2 mRNA表达无明显下降(P＞0.05)。
结论:
1.高浓度小牛血清可诱导肝细胞的脂肪变性:控制高脂因素对肝细胞的脂肪变性程度有改善作用。
2.大黄素可降低脂肪变性肝细胞的TG水平。
3.脂质在肝细胞内的蓄积可能与细胞内UCP2 mRNA表达上调有关。大黄素降低TG的作用可能与脂质代谢其他相关基因的调控有关。
Objective:
To observe the effects of Emodin on expression of UCP2 mRNA in steatotic hepatocytes,to explore the possible mechanism in treating nonalcoholic fatty liver disease.
Methods:
1.Establishing the model of hepatocyte steatosis:A model of hepatocyte steatosis was established by 50%calf serum.Lipid droplets in hepatocytes were observed by inverted microscope after oil red-O staining.The levels ofALT,AST,ALP,LDH in the medium and TG in the hepatocytes were detected.
2.Selecting the appropriate concentration of emodin,the appropriate concentration and treatment time were selected by MTT assay.
3.Index detecting:After the model of hepatocyte steatosis was established,it was divided into 5 groups:normal group,model group,spontaneous recovery group,emodin group with the concentration of 5μM and 10μM..The level of TG in the hepatocytes was detected by automatic biochemical analyzer afer emodin treating 24h and 48h respectively.The expression of UCP2 mRNA in each group was detected by RT-PCR.afer emodin treating 24h.
Results:
1.Steatosis model:The model of hepatocyte steatosis was established by 50%calf serum successfully.Orange red and red lipid droplets were observed by inverted microscope in the model group after oil red-o staining,but there were less in the normal group.Compared with the normal group,the levels of AST,LDH and cellular TG were increased in the 24h model group(P＜0.01),but the levels of ALT and ALP presented no significant difference(P＞0.05).The levels of ALT,LDH,AST,ALP and the content of TG in the hepatocytes were increased significantly in the 48h and 72h model group(P＜0.01,P＜0.05).
2.Content of TG:After cultured with emodin for 24h,compared with the model group, content of TG in spontaneous recovery group were decreased significantly(P＜0.01), compared with the spontaneous recovery group,content of TG in 10μM emodin group was decreased significantly(P＜0.05),5μM emodin group presented no significant difference (P＞0.05).Orange red and red lipid droplets were observed in the model group;Compared with the model group,orange red and red lipid droplets were less in normal group, spontaneous recovery group,5μM emodin group and10μM emodin group.After cultured with emodin for 48h,compared with the spontaneous group,the treatment groups presented no significant difference(P＞0.05).Orange red and red lipid droplets were observed in the model group,other groups were less than mode! group,but it presented no difference between spontaneous recorvery group and treatment groups observed by inverted microscope.
3.The expression of UCP2 mRNA:Compared with the normal group,the expression of UCP2 mRNA in the hepatocytes of model group was higher which was statistically significant(P＜0.01).Compared with the spontaneous recorvety group,expression of UCP2 mRNA in hepatocytes of treatment groups presented no significant difference(P＞0.05).
Conclusion:
1.High consistence serurn could induce steatosis hepatocyte model;controling high consistence serum was significant in ameliorate steatosis status.
2.Emodin could degrade the level of TG in steatotic hepatocytes.
3.The deposition of lipid in hepatocytes might be relative with the upregulate of UCP2 mRNA.The function of decreasing cellular TG by emodin might have the participance of other genes correlated with lipid metabolism.
观察大黄素对脂肪变性L02肝细胞UCP2 mRNA表达的影响,探讨其对脂变肝细胞的降脂作用和机制。
方法:
1.复制模型:以L02肝细胞为研究对象,用含50%小牛血清的1640培养基孵育L02肝细胞48h,建立肝细胞脂肪变性模型,用油红O染色,倒置显微镜观察肝细胞的脂滴积聚情况,检测细胞培养上清肝酶(ALT、AST、ALP、LDH)和细胞内甘油三酯(TG)的变化。
2.筛选药物浓度:采用MTT法测定大黄素作用于脂肪变性肝细胞的适宜浓度。
3.指标检测:模型复制成功后,分为4组:模型组、自然恢复组、大黄素高剂量组、大黄素低剂量组,同时设立正常对照组。药物作用24h、48h后,分别采用全自动生化分析仪检测肝细胞内TG含量的变化。采用RT-PCR法检测各组孵育24h后肝细胞內UCP2 mRNA的表达。
结果:
1.肝细胞脂肪变性模型:成功建立了高浓度小牛血清诱导的L02肝细胞脂肪变性模型,油红O染色显示,模型组在培养24h、48h、72h后,细胞内有逐渐增多的橘红色和红色的脂滴出现,而正常组细胞内则少见。与正常组比较,造模24h后细胞上清AST、LDH含量显著升高(P＜0.01),ALT、ALP未见有显著变化(P＞0.05),肝细胞中TG含量明显升高(P＜0.01);在48h、72h时段,则ALT、AST、ALP、LDH和TG水平都显著升高(P＜0.5,或P＜0.01)。
2.肝脂:大黄素治疗24h后,自然恢复组肝细胞內TG含量与模型组比较明显降低(P＜0.01);与自然恢复组比较,大黄素10μM组肝细胞内TG含量明显降低,差异有统计学意义(P＜0.05),而5μM组无明显降低(P＞0.05)。油红O染色结果显示,模型组细胞浆内见大量橘红色和红色的脂滴,正常组、自然恢复组和大黄素治疗组细胞浆内脂滴数和脂滴的颜色较模型组明显减少,其中大黄素10μM组减少最明显。大黄素治疗48h后,自然恢复组和各治疗组之间无显著性差异(P＞0.05)。油红O染色结果显示,模型组细胞浆内见大量橘红色和红色的脂滴,正常组、自然恢复组和大黄素治疗组细胞浆内脂滴数和脂滴的颜色较模型组明显减少。但大黄素各治疗组与自然恢复组之间比较镜下观察无明显差异。
3.肝细胞UCP2 mRNA的表达:大黄素治疗24t3后,与正常组比较,模型组肝细胞UCP2mRNA表达明显上升,差异有显著性(P＜0.01);各治疗组与自然恢复组比较,UCP2 mRNA表达无明显下降(P＞0.05)。
结论:
1.高浓度小牛血清可诱导肝细胞的脂肪变性:控制高脂因素对肝细胞的脂肪变性程度有改善作用。
2.大黄素可降低脂肪变性肝细胞的TG水平。
3.脂质在肝细胞内的蓄积可能与细胞内UCP2 mRNA表达上调有关。大黄素降低TG的作用可能与脂质代谢其他相关基因的调控有关。
Objective:
To observe the effects of Emodin on expression of UCP2 mRNA in steatotic hepatocytes,to explore the possible mechanism in treating nonalcoholic fatty liver disease.
Methods:
1.Establishing the model of hepatocyte steatosis:A model of hepatocyte steatosis was established by 50%calf serum.Lipid droplets in hepatocytes were observed by inverted microscope after oil red-O staining.The levels ofALT,AST,ALP,LDH in the medium and TG in the hepatocytes were detected.
2.Selecting the appropriate concentration of emodin,the appropriate concentration and treatment time were selected by MTT assay.
3.Index detecting:After the model of hepatocyte steatosis was established,it was divided into 5 groups:normal group,model group,spontaneous recovery group,emodin group with the concentration of 5μM and 10μM..The level of TG in the hepatocytes was detected by automatic biochemical analyzer afer emodin treating 24h and 48h respectively.The expression of UCP2 mRNA in each group was detected by RT-PCR.afer emodin treating 24h.
Results:
1.Steatosis model:The model of hepatocyte steatosis was established by 50%calf serum successfully.Orange red and red lipid droplets were observed by inverted microscope in the model group after oil red-o staining,but there were less in the normal group.Compared with the normal group,the levels of AST,LDH and cellular TG were increased in the 24h model group(P＜0.01),but the levels of ALT and ALP presented no significant difference(P＞0.05).The levels of ALT,LDH,AST,ALP and the content of TG in the hepatocytes were increased significantly in the 48h and 72h model group(P＜0.01,P＜0.05).
2.Content of TG:After cultured with emodin for 24h,compared with the model group, content of TG in spontaneous recovery group were decreased significantly(P＜0.01), compared with the spontaneous recovery group,content of TG in 10μM emodin group was decreased significantly(P＜0.05),5μM emodin group presented no significant difference (P＞0.05).Orange red and red lipid droplets were observed in the model group;Compared with the model group,orange red and red lipid droplets were less in normal group, spontaneous recovery group,5μM emodin group and10μM emodin group.After cultured with emodin for 48h,compared with the spontaneous group,the treatment groups presented no significant difference(P＞0.05).Orange red and red lipid droplets were observed in the model group,other groups were less than mode! group,but it presented no difference between spontaneous recorvery group and treatment groups observed by inverted microscope.
3.The expression of UCP2 mRNA:Compared with the normal group,the expression of UCP2 mRNA in the hepatocytes of model group was higher which was statistically significant(P＜0.01).Compared with the spontaneous recorvety group,expression of UCP2 mRNA in hepatocytes of treatment groups presented no significant difference(P＞0.05).
Conclusion:
1.High consistence serurn could induce steatosis hepatocyte model;controling high consistence serum was significant in ameliorate steatosis status.
2.Emodin could degrade the level of TG in steatotic hepatocytes.
3.The deposition of lipid in hepatocytes might be relative with the upregulate of UCP2 mRNA.The function of decreasing cellular TG by emodin might have the participance of other genes correlated with lipid metabolism.
引文
[1]Chu CJ,Lu RH,Chang CY,Wu MY,Lee SD.Risk factors associated with non-alcoholic fatty liver disease in Chinese patients and the role of tumor necrosis factor-alpha[J].Hepatogastroenterology,2007;54(79):2099-2102.
[2]Zafrani.ES.Non-alcoholic fatty liver disease:an emerging pathological spectrum[J].Virchows Arch,2004;444(25):3-12.
[3]Day CP.Pathogenesis of steatohepatitis[J].Best Pract Res Clin Gastroenterol,2002;16(7):663-678.
[4]丁艳,黄志华.大黄素药理作用研究进展[J].中药药理与临床2007;23(5):236-237
[5]Falck-Ytter Y,Younossi ZM,Zhang CY,Baffy G,Marchesini.Clinical features and natural history of nonalcoholic steatosis syndromes[J].Semin liver,2001(1);21:17-20
[6]Sanyal,AJ,AGA..Technical review on nonalcoholic fatty disease[J].Gastroenterology,2002;123(7):1705-1725.
[7]Park SH,Jeon WK,Kim SH,Amy CM,Williams-Ahlf B,Naggert J.Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults[J].J Gastroenterol Hepatol,2006;21:138-143
[8]范建高,曾民德.脂肪性肝病[M].北京:人民卫生出版社,2005:386-387.
[9]曾民德.重视非酒精性脂肪性肝病的研究[J].中华肝脏病杂志,2003;2(11):69-70
[10]Utzscheider KM,Kahn SE.Review:The role of insulin resistance in nonalcoholic fatty liver disease[J].J Clin Endocrinol Metab,2006;91(12):4753-4761
[11]Day CP.Steatohepatitis:a tale or two "hit"?[J].Gastroenterology,1998;114(18):842-845.
[12]Jimba S,Nakagami T,Takahashi M,Wakamatsu T,Hirota Y,Iwamoto Y,Wasada T.Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults[J].Diabet Med,2005,22(9):1141-1145
[13]Browning JD,Horton JD.Molecular mediators of hepatic steatosi an liver injury.[J]Clin Invest,2004;114(23):147-52.
[14]Shimada M,Hash E,Kaneda H,Noguchi S,Hayashi N.Nonalcoholic for liver fibrosis [J].Hepatology Research,2002;24(5):345-347
[I5]Liu YF,HerschkovitzA,Boura-HalfonS,DonnellyKL,,SmithCI.Serine phosphorylation proximal to its phosphotyrosine binding domain inhibits insulin receptor substrate function and promotes insulin resistance.[J].MolCellBio,2004;24(21):9668-9681.
[16]Grundy SM,Brewer HB Jr,Cleeman JI,Brizi M.Morselli-labate AM.Definition of Metabolic syndrome[J].Circulation,2004;109(3):433-438
[17]Chittutri S,Abeggunasekera S,Farrell GC,Weltman MD,Farrell GC,HallP.NASH and insulin resistance:insulin hypersecretion and specific association with the insuLin resistanc syndrome[J].Hepatology,2002;35(2):373-379
[18]曹民德脂肪肝发病机制及其“二次打击”假设[J].中华消化杂志,2002:22(3):167-168.
[19]姚树坤.酒精性肝病发病机理的研究进展[J].现代消化及介入诊疗,2007:12(4):232-234.
[20]Gianluigi Vendenmiale,Ignazio Grattalgiano,Emanuele Altomare.Mitochondrial oxidative injury and energy metabolism alteration in rat fatty liver:Effect of the nutritional status[J].Hepatology,2001,33(4):808-815.
[21]曹友德,李桂生,李朝晖.高脂血症和游离脂肪酸与脂肪肝的相关性调查[J].中国现代医学杂志,2007;17(4):461-463.
[22]李少东,李红山,冯琴.脂肪肝中医证型分类的文献分析[J].中西医结合肝脏病杂志,2006;16(4):255-257.
[23]邓银泉,范小芬.脂肪肝中医证型与血生化指标的关系[J].浙江中西医结合杂志,2001;11(3):138-140.
[24]郭美姿,李孝生,沈鼎明.大黄酸对大鼠肝纤维化形成的影响[J].中华肝脏病杂志,2003;11(1):26-29.
[25]王新华.泽泻研究进展[J].中草药,1999;30(7):557-578.
[26]梁扩寰,李绍白.肝脏病学[M].人民卫生出版社,1995:731.
[27]中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.NAFLD诊疗指南[J].实用肝脏病杂志,2007;10(1):1-3
[28]孙大炜,孙宝华,徐晓莉,郑博文.他汀类调脂药治疗脂肪肝的试验性研究[J].哈尔滨医药,2006;26(5):60-61
[29]邓建伟,郭栋,周宏灏.他汀类降血脂药物的药代动力学研究进展[J].中国临床药理学与治疗学,2007;12(8):850-860
[30]张琦,杨小平,张晓龙,张岳玺.凯西莱治疗脂肪肝146例疗效观察[J].实用肝脏病杂志,2004;7(1):42-43
[31]许兵华,程井军.健肝消脂汤治疗脂肪肝的临床观察[J].湖北中医杂志,2007;29(8):31-32
[32]朱建明.益肝降脂活血方治疗脂肪肝40例[J].陕西中医,2007;28(9):1128-1129
[33]Bahrami H.Nonalcoholic fatty liver disease in developing countries[J].World J,Gastroenterol,2005;11(4):3808-3809
[34]Voci A,Demori I,Franzi AT,Fugassa E,Lanni A.Uncoupling protein 2 mRNA expression and respiratory parameters in Kupfer cells isolated from euthyroid and hyperthyroid rat livers[J].Eur,Endocrino 2001;145(1 ):317 -322
[35]Fleury C,Neverova M,Collins S.Uncoupling protein-2:a novel gene linked to obesity and hyperinsulinemia[J].Nat Genet,1997;15(3):269-272.
[36]Lentes KU,Tu N,Chen H.Genomic organization and mutational analysis of the human UCP2gene,a prime candidate gene for human obesity[J].J Recept Signal Transduct Res,1999;19(1-4):229-244.
[37]Nagy TR,Blaylock ML,Garvey WT.Role of UCP2 and UCP3 in nutrition and obesity[J].Nutrition,2004;20(1):139-144.
[38]Gonzalez-Yanes C,Sanchez-Margalet V.Pancreastatin,a chromogranin A-derived peptide,inhibits leptin and enhances UCP-2 expression in isolated rat ad -ipocytes[J].CellMol life Sci,2003;60(12):2749-2756.
[39]Diehl AM.Nonalcoholic fatty disease abnormalities in macropHage function andcytokines[J].Am J PHysiol,2002;282:1-5.
[40]Harrison SA,Diehl AM.Fat and the liver:a molecular overview[J].Semin Gastrointest Dis,2002:13(1 ):3-16.
[41]Wanless IR,Shiota K.The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases:a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis.Sem in Liver Dis,2004,24(1):99-106.
[42]Mancini FP,Sabatino L,Colantuoni V.Variants of uncoupling protein-2 gene and obesity:interaction with peroxisome proliferator -activated receptorgamma2[J].CLin Endocrinol (Oxf),2003;59(6):817-822.
[43]Chan CB,Saleh MC,Koshkin V,Li J,Lu C,Ikeda Y,Suehiro T.Uncoupling protein 2 and is let function[J].Diabetes,2004;53(11):136-142.
[44]顾鸣宁.胰岛素抵抗与脂肪肝[J].国外医学.内分泌学分册,2003;23(2):32-33.
[45]Saleh J,Snideman AD,Cianfone K.Regulation of plasma fatty acid metabolism[J]Clin Chem Acta,1999;286(5):163-180.
[46]Chavin KD,YangS,Lin HZ,Frebin V.Obesity induces expressiong of uncoupling protein-2 in he patocytes and promotes liver ATP depletion[J].Bio Chem,1999;27(4):5692o5700
[47]Rashid A,Wu TC,Huang,CC.Mitochondrial protens that regulate opoptosis and necrosis are in duced in mouse fatty liver[J].Hepatology,1999;29(3):154-158
[48]Nagase,Yoshida T,Saito M.Up-regulation of uncoupling proteins by B-adrenergic stimuLation in L6 niyotubes[J].FEBS Lett,2001;494(3):175-180.
[49]Zharg CY,BafLfy G,Perret P.Uncoupling Protein-2 Negatively Regulates Insulin Secretion and Is a Major Link between Obesity,B Cell Dysfunction,and Type 2 Diabetes[J].Cell.2001;105(6):745-755.
[50]Kassis N,Bernard C,PusterLa A.Correlation between pancreatic is let uncoupling protein 2(UCP2)mRNA concentration and insulin status in rats[J].Exp Diabetes Res,2000;1(3):185-193.
[51]Boss O,Hagen T,Lowell BB.Uncoupling proteins 2 and potential regulators of mitochondrial energy metabolism[J].Diabetes,2000;49(2):143-156.
[52]Krauss S,Zhang CY,Scorrano L.Superoxide-mediated activation of uncoupling protein 2 causes pancreatic beta cell dysfunction[J].J clin Invest,2003;112(12):1831 - 1842.
[53]Hayashi S,Yasui H.Essential role of singlet oxygen species in cytochrome P450-dependent substrate oxygenation by rat liver microsomes[J].Drug Metab pHarmacokinet,2005;20(6):14-23.
[54]Ganem D,PrinceAM.Hepatitis B virus infection-natural history and clinical consequences.[J]N EnglMed 2004,350(9):1118-1129.
[55]Chua PK,Wang RY,Lin Masuda T,Suk FM,Shih C.Reduced secretion of virions and hepatitis B virus(HBV) surfaceantigen of a naturally occurring HBV variant correlates with theaccumulation of the small S envelope protein in the endoplasmic reticulum and Golgi apparatus[J].Virol,2005;79(12):13483-13496.
[56]林胜利,卓德徉,王晓红,吴逸园,王珂,吴耀南,张卫光,李载权,唐朝枢.氧化损伤与内质网应激在四氯化碳致大鼠肝脂肪变性中的作用机制[J].中国生物化学与分子生物学报,2006;22(5):422-430
[57]张红锋,杨慧萍,王耀发.乙醇和软脂酸诱导的脂肪肝离体细胞模型[J].华东师范大学学报(自然科学报),2002;(4):88-94
[58]M.Teresa Donato,Agustin Lahoz,Nuria Jimenez.Potential Impact of Steatosis on Cytochrome P450Enzymes of Human Hipatocytes Isolated from Fatty Liver Grafts.[J].Drug Metabolism and Disposition Fast Forward,2006;(34):1556-1562.
[59]Yasuyuki Fujimoto,Jun Onoduka,Koichi J,Homma,Yoshimasa Hag.Long-China Fatty Acids Induce lipid Droplet Formation in a Cultured Human Hepatocyte in a Manner Dependent of Acyl-CoA Synthetase[J].Biol.Pharm.Bull,2006;29(11 ):2174-2180.
[60]Gomez-Lechon,Maria Jose,Donato,Maria Teresa..A human hepatocelluar in vitro model to investigate steatosis[J].Chemico-Biological Interactions,2007;165(2):106-116.
[61]周红宇,阳学风.瘦素对肝细胞三酰甘油沉积的影响[J].临床军医杂志,2006;34(3):265-268.
[62]周红宇,阳学风.两种建立肝细胞脂变模型方法的对比[J].实用医学杂志,2007;23(17):2623-2624.
[63]苏宝亮,陈真,徐厚明,钱之玉.肝细胞脂肪变性模型形态研究[J].中国药科大学学报,2004;35(4):365-367.
[64]刘文全,商红叶,张琴.辨证与辨病结合治疗脂肪肝133例疗效观察[J].新中医,2005;37(9):43-44
[65]胡美兰.脂肪肝的中医病因病机探讨[J].浙江中西医结合杂志,2003;13(12):754-755
[66]潘智敏.杨继荪教授辨治脂肪肝的经验介绍[J].新中医,1999;31(9):7-8
[67]杨海荣,杨志勇,向仁义,杨顺志.益肝降脂胶囊治疗非酒精性脂肪性肝炎68例[J].中西医结合肝病杂志,2007;17(1):56-57
[68]何国强,周世印.脂肪肝从湿毒论治初探.[J]浙江中医杂志,2005;6(2):254-255
[69]于学美,张成博,韩涛,赵益梅.论肝气虚在酒精性脂肪肝发病中的作用[J].山东中医药学学报,2005;29(2):298-299
[70]刘燕玲.浅谈脂肪肝的中医药治疗[J].北京中医药大学学报,1995;18(5):54
[71]谭远忠,魏文斌.中西医结合治疗脂肪肝的观察[J].湖北中医杂志,2007;29(2):26.
[72]李晓陵,孙树凯,王嘉彦,刘丽.64例脂肪肝与CT诊断对照研究[J].中医药信息,2002;19(4):58-59
[73]邓银泉,范小芬.脂肪肝中医证型与血生化指标的关系[J].浙江中西医结合杂志,2001,11(3):138-140
[74]杨钦河,凌家生,吴伟康.中医药治疗脂肪肝的用药规律分析[J].中华中医药杂志,2005;20(9):525-527.
[75]杨钦河,陈孝银,徐云生.降脂宁肝胶囊治疗脂肪肝53例[J].新中医,2003;35(4):53-53.
[76]李晶,李振民.脂肝消胶囊治疗单纯性脂肪肝50例[J].四川中医,2007;25(11):53-4
[77]张翼萃.海桃肝脂宁胶囊治疗脂肪肝的临床观察[J].中药药理与临床,2007;23(5):204-205
[78]王骏,张春燕,陈利群,程玲.针药结合治疗脂肪肝的临床研究[J].中西医结合肝病杂志,2006;16(2):78-79
[79]夏棣其,刘淑娟,杨钦河.电针丰隆及足三里穴对非酒精性脂肪性肝炎大鼠的干预效应[J].中国组织工程研究与临床康复,2007;11(47):9483-9486
[80]张亚兵,邓阿黎.降脂护肝汤治疗脂肪40例[J].中西医结合肝病杂志,2002;12(5):305-306
[81]苗宇船,李瑞华.复方中药防治大鼠脂肪肝的实验研究[J].山西中医学院学报,2003;4(2):15-17
[82]何东仪,胡义扬,刘平,刘成,薛惠明,熊卫国,李风华.肝脂消方对CCl_4诱导大鼠肝脂肪变性时SDHase、ATPase的影响[J].中国中西医结合消化杂志,2001;9(3):133-135
[83]杨饮河,凌家生,吴伟康.中医药治疗脂肪肝的用药规律分析[J].中华中医药杂志,2005;20(6):525-527.
[84]邵鸿娥,李丽芬,崔建亚.枸杞对实验性肝损伤的保护作用[J].中国药物与临床,2004;4(4):268
[85]楼锦英.中药降脂研究现状[J].浙江中医学院学报,2002;26(5):79
[86]沈映君.中药药理学[M].北京:人民卫生出版社,2000:418-419
[87]徐荣花,艾中华,陈丽娟.舒肝活血软坚散结汤治疗脂肪肝36例[J].新中医,2001;33(2):58-59
[88]胡义扬,刘平,刘成,顾宏图,徐列明,刘成海,季光.丹参提取物对CCl_4和DMN诱导的大鼠肝纤维化的影响[J].上海中医药杂志,1999;(10):7-10
[89]康广盛,李显波,孙丽英,于福生.近5年中医药治疗高脂血症的研究进展.[J]中医药信息,2006;23(2):15-17
[90]王宇辉,周超凡.中药降脂研究进展[J].中国中药杂志,1999;24(3):184-185.
[91]王继峰.李峨,李贡字,张秋菊.大豆总黄酮对实验性大鼠高脂血症及脂肪肝的治疗作用[J中国医药学报,2001;16(1):23
[92]吴兆洪,杨永华,柳玉瑾,邰杏芳,沈龙柱,夏翔.首乌冲剂改善高脂血症与高凝状态的临床观察[J].中成药,2001;22(12):844-845
[93]林秋实,陈吉棣.山楂及山楂黄酮预防大鼠脂质代谢紊乱的分子机制研究[J].营养学报,2000;22(2):131-136
[94]汪晓军,张晓刚,张学文,郭兴伯.清肝活血饮抗大鼠脂肪肝的实验研究[J].中国中西医结合消化杂志,2003;11(2):70-72
[95]苏玮,郭群.何首乌的现代药理研究概况[J].中草药,1997;28(2):119-121
[96]江庆澜,马军,徐邦牢,杨辉.虎杖水提液对脂肪肝大鼠的干预效果[J].广州医药,2005;36(3):57-59
[97]孙锡铭,蔡海江,王南,陈秀英.用两性霉素B-细胞模型筛选胆固醇内源性合成抑制剂[J]中西医结合杂志,1989;9(10):604-605.
[98]刘明言,元英进,朱世斌.中药现代化进展[J].中草药,2002;33(3):193-196
[99]Stravitz RT,Sanyal AJ.Drug-induced stcatohepatitis[J].Clira Liver Dis 2003;7(2):435-451
[100]韩萍,成军,李莉.非酒精性脂肪肝炎的研究[J].世界华人消化杂志,2002;10(9):1038-40
[101]梁酉,石梅初,梁艺华,朱玲,张莉.高脂血症与脂肪肝关系的相关性调查[J].实用医学杂志,2002;2(9):146-147。
[102]张喜平.大黄索的药理作用研究概况[J].中国药理学通报,2003;19(8):851-854
[103]张崇本,滕路,时艳,金军华,薛友仿,尚克刚,顾军.大黄素对3T3-L1前脂肪细胞增殖分化及脂肪代谢的影响[J].中国医药杂志,2002;115(7):1101-1117.
[104]董慧,陆付耳,高志强,徐丽君,王开寓,邹欣.大黄素对酒精和高脂饮食饲养诱导的大鼠脂肪肝的影响[J].中国医院药学杂志,2005;25(3):202-204.
[105]董慧,陆付耳,高志强,徐丽君,王开富,邹欣,大黄素治疗高脂饮食饲养诱发的大鼠NAFLD的试验研究[J].中国中西医结合杂志,2006;26(6):64-67.
[106]周利玲,舒筱灿,吴和平,李树平,韩伟,李辉.大黄素干预鹌鹑脂肪肝病变的效果[J].中国临床康复,2006;10(32):58-59.
[107]刘钰瑜,崔燎,吴铁,姚卫民,许碧连,邹丽宜.大黄素对泼尼松致大鼠脂代谢异常的预防作用研究[J].时珍国医国药,2007;18(11):2669-2700.
[108]Imanishi Y,Maeda N,Otoga waK,Wu TC,Huang,CC..Herb medicine Inchinko to regulates PDGF-BB-dependent signaling pathways of hepatic stellated cells in primary culture and attenuates development of liver fibrosis induced by thioacetamide administration in rats[J].J Hepato,2004;41(2):242-250
[109]SRINIVAS G,ANTO R J,SRINIVAS P.Emodin induces apoptosis of human cervical cancer cells through poly(ADP-ribose) polymerase cleavage and activation of caspase-9[J].Eur J Pharmacol,2003;473:117-125.
[110]DongH,Lu FE,Gao ZQ,Semple SJ,Pyke SM,Reynolds GD.Effects of emodin on treatingmurine nonalcoholic fatty liver induced by high caloric laboratory chaw[J].World J Gastroentero,2005;11(9):1339-1344.
[111]Meng KW,Lv Y,Yu L,Mbwambo ZH,ApersS,MoshiM.Effects of emodin and double blood supplies on liver regeneration of reduced size graft liver in rat model[J].World J Gastroenteml,2005;11(19):2941-2944.
[112]Lin CC,chang cH,yangjj,KongLD,Chung J.Hepatopnoteetive effects of emodin from Ventilago leiovarpaj[J].Ethopharmacol.1996;52(2):107-111.
[113]展玉涛,卫新革,陈颖伟,潘勤,徐芹芳,李定国.大黄素对肝纤维化大鼠血清透明质酸的影响.[J].中西医结合肝病杂志,1999;9(4):27-28
[114]展玉涛,魏红山,工志荣,黄新,徐芹芳,李定国.大黄素对大鼠四氯化碳性肝损伤保护作用的实验研究[J].中国中医药科技,2000;7(1):30-31
[115]焦河玲,黄兆胜,贾建功.大黄素对四氯化碳损伤原代培养大鼠肝细胞的保护作用[J].河南中医,2000;20(5):20-22
[116]JungHA,ChungHY,Yokozawa T,UebavashiH,Dillon JS.Alaternin and emodin with hydroxyl radical inhibitory and/or scavenging activities and hepatoprotective activity on tacrine- induced cytotoxicity in HepG2 cells[J].Arch Pharm Res,2004;27(9):947-953
[117]GuiM,ZhangYF,Xiao ZY,Yunru C.Inhibitory Effect of Emodin on Tissue Inhibitor of Metall oproteinases-1(TIMP-1) Expression in Rat Hepatic Stellate Cells[J].DigDis Sc,2007;52(1):200-207
[118]MengKW,LvY,Yul,Barnard DL,Huffman JH,Morris.Effectsofemodin and double blood suppLies on liver regeneration of reduced size graft liver in ratmode[J].World J Gastroentero,2005;11(19):2941-2944
[119]刘凯,李传富,蔡海江.原发性、家族性高胆固醇血症药物治疗进展[J].中国中西医结合杂志,1991;11(9):315-316.
[120]蔡海江,范乐明.中药丹参及大黄对实验性高脂血症大鼠LDL受体基因表达的影响[J].中国病理生理杂志,1993;9(1):108-109
[121]胡昌江,马列,何学梅,瞿燕,禹玉洪,胥云.九制大黄蒽醌衍生物对动物高脂血症及血流变学的影响[J].中成药,2001;23(1):31-33
[122]Huang SS,Yeh SF,H ong CY,FinkBD.Effect of anthraquinone derivatives on lipid peroxidation in rat heart mitochondria:Structure activity relationship[J].JNat Prod,1995;58(9):1365-1371
[123]罗霄山.芦荟大黄索对CCl_4损伤原代培养大鼠肝细胞的保护作用[J].中医药学刊,2003;21(7):1102-1103.
[124]ChenY,Yangl,LeeTJ,Wang,HH,Chung J.Oroxylin Ainhibition of lipopoly saccharide-induced iNOS and COX-2 gene expression viasuppression of nuclear factor-kappaB activation[J].Biochem Pharmacol.2000,Junl;59(11 ):1445-1447.
[125]王文俊,吴咸中,姚智,李会强,卢奕.中药有效成分对IL-2及IFN-r分泌的影响[J].天津中医,1995;12(2):23-24
[126]Kuo YC,Meng HC,Tsai Wj.Regulation of ilproliferation inflamm atory cytokine production and calciumm obilization in primary human T imphocytes by emodin from Poiygonum hypoleucum Ohwi[J].Inflamm Res,2001;50(2):73-82
[127]王文俊,吴咸中,姚智,李会强.大黄素、丹参素对单核细胞分泌炎性细胞因子的调节[J].中国免疫 学杂志,1995;11(6):370-372
[128]Xu P,Zhang XG,Li YM,Yu CH,Xu L,Xu GY.Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease(NAFLD) in rats[J].J Zhejiang Univ Sci B,2006;7(2):627-633
[129]Browning JD,Latruffe N,Vamecq J,Horton JD.Molecular mediators of hepatic steatosis and liver injury[J].J Clin Invest 2004;114:147-152
[130]周红宇,阳学风.瘦素对肝细胞三酰甘油沉积的影响[J].临床军医杂志,2006;34(3):265-268.
[131]曾民德.脂肪肝发生机制及其“二次打击”假设.[J]中华消化杂志,2002;22(16):167-168
[132]王家駹.非酒精性脂肪性肝炎病理病因和发病机制[J].中华消化杂志,2002;22(17):360-362
[133]林秀珍,马德禄,崔荣芬.大黄素及番泻甙和大黄多糖对培养大鼠肝细胞内离钙浓度的影响[J].中国中西医结合杂志,1995;15(7):419-419.
[134]Yutaka MASUDA,a Toshihiro AIUCHI.Increase in Intracellular Cat Concentrations and the Corresponding Intracellular Acidification Are Early Steps for Induction of Apoptosis by Geranylgeraniol in HL60 Cells[J].Biol Pharm.Bull,2007;30(5):880-884
[135]Arosio B,Gagliano N,Fusaro,LM.Aloe.Emodin quinine pretreatment reduces acute liver injury induced by carbontertrachloride[J].Pharmacol Toxico,2000;87(5):229-231
[136]董慧,陆付耳,闫中卿,王开富,徐丽君,邹欣.大黄素对原代培养小鼠肝细胞非酒精性脂肪变的影响[J].中国中西医结合消化杂志,2007,8;15(4):222-223
[137]范建高,丁晓东,王国良,徐正婕,田丽艳,郑晓英.非酒精脂肪性肝病大鼠肝脏解偶联蛋白2表达及其与能量储备的关系[J].中华肝脏病杂志,2005;13(5):374-377
[138]代东伶,沈薇,张晓红,渝海峰.高脂饮食对实验性大鼠非酒精性脂肪肝UCP2表达的影响[J].国际消化病杂志,2006;26(1):64-66
[139]高沿航,李玉琴,王丹,朴云峰.非酒精性脂肪肝临床特点分析[J].吉林医学,2003;24(2):130-131
[2]Zafrani.ES.Non-alcoholic fatty liver disease:an emerging pathological spectrum[J].Virchows Arch,2004;444(25):3-12.
[3]Day CP.Pathogenesis of steatohepatitis[J].Best Pract Res Clin Gastroenterol,2002;16(7):663-678.
[4]丁艳,黄志华.大黄素药理作用研究进展[J].中药药理与临床2007;23(5):236-237
[5]Falck-Ytter Y,Younossi ZM,Zhang CY,Baffy G,Marchesini.Clinical features and natural history of nonalcoholic steatosis syndromes[J].Semin liver,2001(1);21:17-20
[6]Sanyal,AJ,AGA..Technical review on nonalcoholic fatty disease[J].Gastroenterology,2002;123(7):1705-1725.
[7]Park SH,Jeon WK,Kim SH,Amy CM,Williams-Ahlf B,Naggert J.Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults[J].J Gastroenterol Hepatol,2006;21:138-143
[8]范建高,曾民德.脂肪性肝病[M].北京:人民卫生出版社,2005:386-387.
[9]曾民德.重视非酒精性脂肪性肝病的研究[J].中华肝脏病杂志,2003;2(11):69-70
[10]Utzscheider KM,Kahn SE.Review:The role of insulin resistance in nonalcoholic fatty liver disease[J].J Clin Endocrinol Metab,2006;91(12):4753-4761
[11]Day CP.Steatohepatitis:a tale or two "hit"?[J].Gastroenterology,1998;114(18):842-845.
[12]Jimba S,Nakagami T,Takahashi M,Wakamatsu T,Hirota Y,Iwamoto Y,Wasada T.Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults[J].Diabet Med,2005,22(9):1141-1145
[13]Browning JD,Horton JD.Molecular mediators of hepatic steatosi an liver injury.[J]Clin Invest,2004;114(23):147-52.
[14]Shimada M,Hash E,Kaneda H,Noguchi S,Hayashi N.Nonalcoholic for liver fibrosis [J].Hepatology Research,2002;24(5):345-347
[I5]Liu YF,HerschkovitzA,Boura-HalfonS,DonnellyKL,,SmithCI.Serine phosphorylation proximal to its phosphotyrosine binding domain inhibits insulin receptor substrate function and promotes insulin resistance.[J].MolCellBio,2004;24(21):9668-9681.
[16]Grundy SM,Brewer HB Jr,Cleeman JI,Brizi M.Morselli-labate AM.Definition of Metabolic syndrome[J].Circulation,2004;109(3):433-438
[17]Chittutri S,Abeggunasekera S,Farrell GC,Weltman MD,Farrell GC,HallP.NASH and insulin resistance:insulin hypersecretion and specific association with the insuLin resistanc syndrome[J].Hepatology,2002;35(2):373-379
[18]曹民德脂肪肝发病机制及其“二次打击”假设[J].中华消化杂志,2002:22(3):167-168.
[19]姚树坤.酒精性肝病发病机理的研究进展[J].现代消化及介入诊疗,2007:12(4):232-234.
[20]Gianluigi Vendenmiale,Ignazio Grattalgiano,Emanuele Altomare.Mitochondrial oxidative injury and energy metabolism alteration in rat fatty liver:Effect of the nutritional status[J].Hepatology,2001,33(4):808-815.
[21]曹友德,李桂生,李朝晖.高脂血症和游离脂肪酸与脂肪肝的相关性调查[J].中国现代医学杂志,2007;17(4):461-463.
[22]李少东,李红山,冯琴.脂肪肝中医证型分类的文献分析[J].中西医结合肝脏病杂志,2006;16(4):255-257.
[23]邓银泉,范小芬.脂肪肝中医证型与血生化指标的关系[J].浙江中西医结合杂志,2001;11(3):138-140.
[24]郭美姿,李孝生,沈鼎明.大黄酸对大鼠肝纤维化形成的影响[J].中华肝脏病杂志,2003;11(1):26-29.
[25]王新华.泽泻研究进展[J].中草药,1999;30(7):557-578.
[26]梁扩寰,李绍白.肝脏病学[M].人民卫生出版社,1995:731.
[27]中华医学会肝脏病学分会脂肪肝和酒精性肝病学组.NAFLD诊疗指南[J].实用肝脏病杂志,2007;10(1):1-3
[28]孙大炜,孙宝华,徐晓莉,郑博文.他汀类调脂药治疗脂肪肝的试验性研究[J].哈尔滨医药,2006;26(5):60-61
[29]邓建伟,郭栋,周宏灏.他汀类降血脂药物的药代动力学研究进展[J].中国临床药理学与治疗学,2007;12(8):850-860
[30]张琦,杨小平,张晓龙,张岳玺.凯西莱治疗脂肪肝146例疗效观察[J].实用肝脏病杂志,2004;7(1):42-43
[31]许兵华,程井军.健肝消脂汤治疗脂肪肝的临床观察[J].湖北中医杂志,2007;29(8):31-32
[32]朱建明.益肝降脂活血方治疗脂肪肝40例[J].陕西中医,2007;28(9):1128-1129
[33]Bahrami H.Nonalcoholic fatty liver disease in developing countries[J].World J,Gastroenterol,2005;11(4):3808-3809
[34]Voci A,Demori I,Franzi AT,Fugassa E,Lanni A.Uncoupling protein 2 mRNA expression and respiratory parameters in Kupfer cells isolated from euthyroid and hyperthyroid rat livers[J].Eur,Endocrino 2001;145(1 ):317 -322
[35]Fleury C,Neverova M,Collins S.Uncoupling protein-2:a novel gene linked to obesity and hyperinsulinemia[J].Nat Genet,1997;15(3):269-272.
[36]Lentes KU,Tu N,Chen H.Genomic organization and mutational analysis of the human UCP2gene,a prime candidate gene for human obesity[J].J Recept Signal Transduct Res,1999;19(1-4):229-244.
[37]Nagy TR,Blaylock ML,Garvey WT.Role of UCP2 and UCP3 in nutrition and obesity[J].Nutrition,2004;20(1):139-144.
[38]Gonzalez-Yanes C,Sanchez-Margalet V.Pancreastatin,a chromogranin A-derived peptide,inhibits leptin and enhances UCP-2 expression in isolated rat ad -ipocytes[J].CellMol life Sci,2003;60(12):2749-2756.
[39]Diehl AM.Nonalcoholic fatty disease abnormalities in macropHage function andcytokines[J].Am J PHysiol,2002;282:1-5.
[40]Harrison SA,Diehl AM.Fat and the liver:a molecular overview[J].Semin Gastrointest Dis,2002:13(1 ):3-16.
[41]Wanless IR,Shiota K.The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases:a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis.Sem in Liver Dis,2004,24(1):99-106.
[42]Mancini FP,Sabatino L,Colantuoni V.Variants of uncoupling protein-2 gene and obesity:interaction with peroxisome proliferator -activated receptorgamma2[J].CLin Endocrinol (Oxf),2003;59(6):817-822.
[43]Chan CB,Saleh MC,Koshkin V,Li J,Lu C,Ikeda Y,Suehiro T.Uncoupling protein 2 and is let function[J].Diabetes,2004;53(11):136-142.
[44]顾鸣宁.胰岛素抵抗与脂肪肝[J].国外医学.内分泌学分册,2003;23(2):32-33.
[45]Saleh J,Snideman AD,Cianfone K.Regulation of plasma fatty acid metabolism[J]Clin Chem Acta,1999;286(5):163-180.
[46]Chavin KD,YangS,Lin HZ,Frebin V.Obesity induces expressiong of uncoupling protein-2 in he patocytes and promotes liver ATP depletion[J].Bio Chem,1999;27(4):5692o5700
[47]Rashid A,Wu TC,Huang,CC.Mitochondrial protens that regulate opoptosis and necrosis are in duced in mouse fatty liver[J].Hepatology,1999;29(3):154-158
[48]Nagase,Yoshida T,Saito M.Up-regulation of uncoupling proteins by B-adrenergic stimuLation in L6 niyotubes[J].FEBS Lett,2001;494(3):175-180.
[49]Zharg CY,BafLfy G,Perret P.Uncoupling Protein-2 Negatively Regulates Insulin Secretion and Is a Major Link between Obesity,B Cell Dysfunction,and Type 2 Diabetes[J].Cell.2001;105(6):745-755.
[50]Kassis N,Bernard C,PusterLa A.Correlation between pancreatic is let uncoupling protein 2(UCP2)mRNA concentration and insulin status in rats[J].Exp Diabetes Res,2000;1(3):185-193.
[51]Boss O,Hagen T,Lowell BB.Uncoupling proteins 2 and potential regulators of mitochondrial energy metabolism[J].Diabetes,2000;49(2):143-156.
[52]Krauss S,Zhang CY,Scorrano L.Superoxide-mediated activation of uncoupling protein 2 causes pancreatic beta cell dysfunction[J].J clin Invest,2003;112(12):1831 - 1842.
[53]Hayashi S,Yasui H.Essential role of singlet oxygen species in cytochrome P450-dependent substrate oxygenation by rat liver microsomes[J].Drug Metab pHarmacokinet,2005;20(6):14-23.
[54]Ganem D,PrinceAM.Hepatitis B virus infection-natural history and clinical consequences.[J]N EnglMed 2004,350(9):1118-1129.
[55]Chua PK,Wang RY,Lin Masuda T,Suk FM,Shih C.Reduced secretion of virions and hepatitis B virus(HBV) surfaceantigen of a naturally occurring HBV variant correlates with theaccumulation of the small S envelope protein in the endoplasmic reticulum and Golgi apparatus[J].Virol,2005;79(12):13483-13496.
[56]林胜利,卓德徉,王晓红,吴逸园,王珂,吴耀南,张卫光,李载权,唐朝枢.氧化损伤与内质网应激在四氯化碳致大鼠肝脂肪变性中的作用机制[J].中国生物化学与分子生物学报,2006;22(5):422-430
[57]张红锋,杨慧萍,王耀发.乙醇和软脂酸诱导的脂肪肝离体细胞模型[J].华东师范大学学报(自然科学报),2002;(4):88-94
[58]M.Teresa Donato,Agustin Lahoz,Nuria Jimenez.Potential Impact of Steatosis on Cytochrome P450Enzymes of Human Hipatocytes Isolated from Fatty Liver Grafts.[J].Drug Metabolism and Disposition Fast Forward,2006;(34):1556-1562.
[59]Yasuyuki Fujimoto,Jun Onoduka,Koichi J,Homma,Yoshimasa Hag.Long-China Fatty Acids Induce lipid Droplet Formation in a Cultured Human Hepatocyte in a Manner Dependent of Acyl-CoA Synthetase[J].Biol.Pharm.Bull,2006;29(11 ):2174-2180.
[60]Gomez-Lechon,Maria Jose,Donato,Maria Teresa..A human hepatocelluar in vitro model to investigate steatosis[J].Chemico-Biological Interactions,2007;165(2):106-116.
[61]周红宇,阳学风.瘦素对肝细胞三酰甘油沉积的影响[J].临床军医杂志,2006;34(3):265-268.
[62]周红宇,阳学风.两种建立肝细胞脂变模型方法的对比[J].实用医学杂志,2007;23(17):2623-2624.
[63]苏宝亮,陈真,徐厚明,钱之玉.肝细胞脂肪变性模型形态研究[J].中国药科大学学报,2004;35(4):365-367.
[64]刘文全,商红叶,张琴.辨证与辨病结合治疗脂肪肝133例疗效观察[J].新中医,2005;37(9):43-44
[65]胡美兰.脂肪肝的中医病因病机探讨[J].浙江中西医结合杂志,2003;13(12):754-755
[66]潘智敏.杨继荪教授辨治脂肪肝的经验介绍[J].新中医,1999;31(9):7-8
[67]杨海荣,杨志勇,向仁义,杨顺志.益肝降脂胶囊治疗非酒精性脂肪性肝炎68例[J].中西医结合肝病杂志,2007;17(1):56-57
[68]何国强,周世印.脂肪肝从湿毒论治初探.[J]浙江中医杂志,2005;6(2):254-255
[69]于学美,张成博,韩涛,赵益梅.论肝气虚在酒精性脂肪肝发病中的作用[J].山东中医药学学报,2005;29(2):298-299
[70]刘燕玲.浅谈脂肪肝的中医药治疗[J].北京中医药大学学报,1995;18(5):54
[71]谭远忠,魏文斌.中西医结合治疗脂肪肝的观察[J].湖北中医杂志,2007;29(2):26.
[72]李晓陵,孙树凯,王嘉彦,刘丽.64例脂肪肝与CT诊断对照研究[J].中医药信息,2002;19(4):58-59
[73]邓银泉,范小芬.脂肪肝中医证型与血生化指标的关系[J].浙江中西医结合杂志,2001,11(3):138-140
[74]杨钦河,凌家生,吴伟康.中医药治疗脂肪肝的用药规律分析[J].中华中医药杂志,2005;20(9):525-527.
[75]杨钦河,陈孝银,徐云生.降脂宁肝胶囊治疗脂肪肝53例[J].新中医,2003;35(4):53-53.
[76]李晶,李振民.脂肝消胶囊治疗单纯性脂肪肝50例[J].四川中医,2007;25(11):53-4
[77]张翼萃.海桃肝脂宁胶囊治疗脂肪肝的临床观察[J].中药药理与临床,2007;23(5):204-205
[78]王骏,张春燕,陈利群,程玲.针药结合治疗脂肪肝的临床研究[J].中西医结合肝病杂志,2006;16(2):78-79
[79]夏棣其,刘淑娟,杨钦河.电针丰隆及足三里穴对非酒精性脂肪性肝炎大鼠的干预效应[J].中国组织工程研究与临床康复,2007;11(47):9483-9486
[80]张亚兵,邓阿黎.降脂护肝汤治疗脂肪40例[J].中西医结合肝病杂志,2002;12(5):305-306
[81]苗宇船,李瑞华.复方中药防治大鼠脂肪肝的实验研究[J].山西中医学院学报,2003;4(2):15-17
[82]何东仪,胡义扬,刘平,刘成,薛惠明,熊卫国,李风华.肝脂消方对CCl_4诱导大鼠肝脂肪变性时SDHase、ATPase的影响[J].中国中西医结合消化杂志,2001;9(3):133-135
[83]杨饮河,凌家生,吴伟康.中医药治疗脂肪肝的用药规律分析[J].中华中医药杂志,2005;20(6):525-527.
[84]邵鸿娥,李丽芬,崔建亚.枸杞对实验性肝损伤的保护作用[J].中国药物与临床,2004;4(4):268
[85]楼锦英.中药降脂研究现状[J].浙江中医学院学报,2002;26(5):79
[86]沈映君.中药药理学[M].北京:人民卫生出版社,2000:418-419
[87]徐荣花,艾中华,陈丽娟.舒肝活血软坚散结汤治疗脂肪肝36例[J].新中医,2001;33(2):58-59
[88]胡义扬,刘平,刘成,顾宏图,徐列明,刘成海,季光.丹参提取物对CCl_4和DMN诱导的大鼠肝纤维化的影响[J].上海中医药杂志,1999;(10):7-10
[89]康广盛,李显波,孙丽英,于福生.近5年中医药治疗高脂血症的研究进展.[J]中医药信息,2006;23(2):15-17
[90]王宇辉,周超凡.中药降脂研究进展[J].中国中药杂志,1999;24(3):184-185.
[91]王继峰.李峨,李贡字,张秋菊.大豆总黄酮对实验性大鼠高脂血症及脂肪肝的治疗作用[J中国医药学报,2001;16(1):23
[92]吴兆洪,杨永华,柳玉瑾,邰杏芳,沈龙柱,夏翔.首乌冲剂改善高脂血症与高凝状态的临床观察[J].中成药,2001;22(12):844-845
[93]林秋实,陈吉棣.山楂及山楂黄酮预防大鼠脂质代谢紊乱的分子机制研究[J].营养学报,2000;22(2):131-136
[94]汪晓军,张晓刚,张学文,郭兴伯.清肝活血饮抗大鼠脂肪肝的实验研究[J].中国中西医结合消化杂志,2003;11(2):70-72
[95]苏玮,郭群.何首乌的现代药理研究概况[J].中草药,1997;28(2):119-121
[96]江庆澜,马军,徐邦牢,杨辉.虎杖水提液对脂肪肝大鼠的干预效果[J].广州医药,2005;36(3):57-59
[97]孙锡铭,蔡海江,王南,陈秀英.用两性霉素B-细胞模型筛选胆固醇内源性合成抑制剂[J]中西医结合杂志,1989;9(10):604-605.
[98]刘明言,元英进,朱世斌.中药现代化进展[J].中草药,2002;33(3):193-196
[99]Stravitz RT,Sanyal AJ.Drug-induced stcatohepatitis[J].Clira Liver Dis 2003;7(2):435-451
[100]韩萍,成军,李莉.非酒精性脂肪肝炎的研究[J].世界华人消化杂志,2002;10(9):1038-40
[101]梁酉,石梅初,梁艺华,朱玲,张莉.高脂血症与脂肪肝关系的相关性调查[J].实用医学杂志,2002;2(9):146-147。
[102]张喜平.大黄索的药理作用研究概况[J].中国药理学通报,2003;19(8):851-854
[103]张崇本,滕路,时艳,金军华,薛友仿,尚克刚,顾军.大黄素对3T3-L1前脂肪细胞增殖分化及脂肪代谢的影响[J].中国医药杂志,2002;115(7):1101-1117.
[104]董慧,陆付耳,高志强,徐丽君,王开寓,邹欣.大黄素对酒精和高脂饮食饲养诱导的大鼠脂肪肝的影响[J].中国医院药学杂志,2005;25(3):202-204.
[105]董慧,陆付耳,高志强,徐丽君,王开富,邹欣,大黄素治疗高脂饮食饲养诱发的大鼠NAFLD的试验研究[J].中国中西医结合杂志,2006;26(6):64-67.
[106]周利玲,舒筱灿,吴和平,李树平,韩伟,李辉.大黄素干预鹌鹑脂肪肝病变的效果[J].中国临床康复,2006;10(32):58-59.
[107]刘钰瑜,崔燎,吴铁,姚卫民,许碧连,邹丽宜.大黄素对泼尼松致大鼠脂代谢异常的预防作用研究[J].时珍国医国药,2007;18(11):2669-2700.
[108]Imanishi Y,Maeda N,Otoga waK,Wu TC,Huang,CC..Herb medicine Inchinko to regulates PDGF-BB-dependent signaling pathways of hepatic stellated cells in primary culture and attenuates development of liver fibrosis induced by thioacetamide administration in rats[J].J Hepato,2004;41(2):242-250
[109]SRINIVAS G,ANTO R J,SRINIVAS P.Emodin induces apoptosis of human cervical cancer cells through poly(ADP-ribose) polymerase cleavage and activation of caspase-9[J].Eur J Pharmacol,2003;473:117-125.
[110]DongH,Lu FE,Gao ZQ,Semple SJ,Pyke SM,Reynolds GD.Effects of emodin on treatingmurine nonalcoholic fatty liver induced by high caloric laboratory chaw[J].World J Gastroentero,2005;11(9):1339-1344.
[111]Meng KW,Lv Y,Yu L,Mbwambo ZH,ApersS,MoshiM.Effects of emodin and double blood supplies on liver regeneration of reduced size graft liver in rat model[J].World J Gastroenteml,2005;11(19):2941-2944.
[112]Lin CC,chang cH,yangjj,KongLD,Chung J.Hepatopnoteetive effects of emodin from Ventilago leiovarpaj[J].Ethopharmacol.1996;52(2):107-111.
[113]展玉涛,卫新革,陈颖伟,潘勤,徐芹芳,李定国.大黄素对肝纤维化大鼠血清透明质酸的影响.[J].中西医结合肝病杂志,1999;9(4):27-28
[114]展玉涛,魏红山,工志荣,黄新,徐芹芳,李定国.大黄素对大鼠四氯化碳性肝损伤保护作用的实验研究[J].中国中医药科技,2000;7(1):30-31
[115]焦河玲,黄兆胜,贾建功.大黄素对四氯化碳损伤原代培养大鼠肝细胞的保护作用[J].河南中医,2000;20(5):20-22
[116]JungHA,ChungHY,Yokozawa T,UebavashiH,Dillon JS.Alaternin and emodin with hydroxyl radical inhibitory and/or scavenging activities and hepatoprotective activity on tacrine- induced cytotoxicity in HepG2 cells[J].Arch Pharm Res,2004;27(9):947-953
[117]GuiM,ZhangYF,Xiao ZY,Yunru C.Inhibitory Effect of Emodin on Tissue Inhibitor of Metall oproteinases-1(TIMP-1) Expression in Rat Hepatic Stellate Cells[J].DigDis Sc,2007;52(1):200-207
[118]MengKW,LvY,Yul,Barnard DL,Huffman JH,Morris.Effectsofemodin and double blood suppLies on liver regeneration of reduced size graft liver in ratmode[J].World J Gastroentero,2005;11(19):2941-2944
[119]刘凯,李传富,蔡海江.原发性、家族性高胆固醇血症药物治疗进展[J].中国中西医结合杂志,1991;11(9):315-316.
[120]蔡海江,范乐明.中药丹参及大黄对实验性高脂血症大鼠LDL受体基因表达的影响[J].中国病理生理杂志,1993;9(1):108-109
[121]胡昌江,马列,何学梅,瞿燕,禹玉洪,胥云.九制大黄蒽醌衍生物对动物高脂血症及血流变学的影响[J].中成药,2001;23(1):31-33
[122]Huang SS,Yeh SF,H ong CY,FinkBD.Effect of anthraquinone derivatives on lipid peroxidation in rat heart mitochondria:Structure activity relationship[J].JNat Prod,1995;58(9):1365-1371
[123]罗霄山.芦荟大黄索对CCl_4损伤原代培养大鼠肝细胞的保护作用[J].中医药学刊,2003;21(7):1102-1103.
[124]ChenY,Yangl,LeeTJ,Wang,HH,Chung J.Oroxylin Ainhibition of lipopoly saccharide-induced iNOS and COX-2 gene expression viasuppression of nuclear factor-kappaB activation[J].Biochem Pharmacol.2000,Junl;59(11 ):1445-1447.
[125]王文俊,吴咸中,姚智,李会强,卢奕.中药有效成分对IL-2及IFN-r分泌的影响[J].天津中医,1995;12(2):23-24
[126]Kuo YC,Meng HC,Tsai Wj.Regulation of ilproliferation inflamm atory cytokine production and calciumm obilization in primary human T imphocytes by emodin from Poiygonum hypoleucum Ohwi[J].Inflamm Res,2001;50(2):73-82
[127]王文俊,吴咸中,姚智,李会强.大黄素、丹参素对单核细胞分泌炎性细胞因子的调节[J].中国免疫 学杂志,1995;11(6):370-372
[128]Xu P,Zhang XG,Li YM,Yu CH,Xu L,Xu GY.Research on the protection effect of pioglitazone for non-alcoholic fatty liver disease(NAFLD) in rats[J].J Zhejiang Univ Sci B,2006;7(2):627-633
[129]Browning JD,Latruffe N,Vamecq J,Horton JD.Molecular mediators of hepatic steatosis and liver injury[J].J Clin Invest 2004;114:147-152
[130]周红宇,阳学风.瘦素对肝细胞三酰甘油沉积的影响[J].临床军医杂志,2006;34(3):265-268.
[131]曾民德.脂肪肝发生机制及其“二次打击”假设.[J]中华消化杂志,2002;22(16):167-168
[132]王家駹.非酒精性脂肪性肝炎病理病因和发病机制[J].中华消化杂志,2002;22(17):360-362
[133]林秀珍,马德禄,崔荣芬.大黄素及番泻甙和大黄多糖对培养大鼠肝细胞内离钙浓度的影响[J].中国中西医结合杂志,1995;15(7):419-419.
[134]Yutaka MASUDA,a Toshihiro AIUCHI.Increase in Intracellular Cat Concentrations and the Corresponding Intracellular Acidification Are Early Steps for Induction of Apoptosis by Geranylgeraniol in HL60 Cells[J].Biol Pharm.Bull,2007;30(5):880-884
[135]Arosio B,Gagliano N,Fusaro,LM.Aloe.Emodin quinine pretreatment reduces acute liver injury induced by carbontertrachloride[J].Pharmacol Toxico,2000;87(5):229-231
[136]董慧,陆付耳,闫中卿,王开富,徐丽君,邹欣.大黄素对原代培养小鼠肝细胞非酒精性脂肪变的影响[J].中国中西医结合消化杂志,2007,8;15(4):222-223
[137]范建高,丁晓东,王国良,徐正婕,田丽艳,郑晓英.非酒精脂肪性肝病大鼠肝脏解偶联蛋白2表达及其与能量储备的关系[J].中华肝脏病杂志,2005;13(5):374-377
[138]代东伶,沈薇,张晓红,渝海峰.高脂饮食对实验性大鼠非酒精性脂肪肝UCP2表达的影响[J].国际消化病杂志,2006;26(1):64-66
[139]高沿航,李玉琴,王丹,朴云峰.非酒精性脂肪肝临床特点分析[J].吉林医学,2003;24(2):130-131